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Recent changes in American and European guidelines on the management of 
arterial hypertension have caused a considerable shift in the landscape of 
hypertension management. The 2017 American College of Cardiology/American 
Heart Association/American Society of Hypertension guideline recommends an 
office visit blood pressure (BP) > 130/80 mmHg as the new threshold for diagnosis 
of hypertension, and states that the treatment goal for all hypertensive patients 
should be lowered to < 130/80 mmHg. In contrast, the 2018 European guideline 
maintains the diagnostic threshold of hypertension at 140/90 mmHg. However, 
despite their differences in thresholds for diagnosis of hypertension, both 
guidelines are in agreement that treatment should be considered in patients with 
BPs in the range of 130 to 139/80 to 89 mmHg if they have high cardiovascular 
risk. The results from the Systolic Blood Pressure Intervention Trial (SPRINT) 
study and recent meta-analyses suggest that BP lowering with antihypertensive 
treatment may be beneficial in reducing cardiovascular event rates in subjects 
with high-normal BP or stage 1 hypertension according to the new American 
guideline. However, intensive BP lowering is associated with increased incidence 
of treatment-associated adverse events, and evidence suggests that BP lowering 
below 120/70 mmHg increases the risk of cardiovascular events. In this review, we 
discuss the evidence supporting antihypertensive treatment in subjects with 
high-normal BP and discuss the specific subgroup of subjects that might benefit 
from BP lowering.
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INTRODUCTION
Recent changes in American and European guidelines 
on the management of arterial hypertension have 
caused a considerable shift in the landscape of hyper-
tension management [1,2]. The 2017 American College 
of Cardiology/American Heart Association/American 
Society of Hypertension guideline recommends a new 
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threshold for diagnosis of hypertension, i.e., an office 
visit blood pressure (BP) > 130/80 mmHg, and states 
that the treatment goal for all hypertensive patients 
should be lowered to < 130/80 mmHg [1]. In addition, 
the new American guideline recommends that drug 
treatment should be considered in high-risk patients 
with stage 1 hypertension, and in those with BPs in the 
range of 130/80 to 140/90 mmHg and an arteriosclerotic 
vascular disease risk score of > 10% or cardiovascular 
disease (CVD) [1]. In contrast, the new 2018 European 
guideline maintains the diagnostic threshold of hyper-
tension at 140/90 mmHg [2]. However, the European 
guideline recommends a strict target systolic blood 
pressure (SBP) goal of ≤ 130 mmHg for most hyperten-
sive patients, with the exception of those with chronic 
kidney disease (CKD) or advanced age (> 65 years); fur-
thermore, the diastolic blood pressure (DBP) should be 
controlled in the range of 70 to 80 mmHg [2]. In addi-
tion, the new European guideline suggests that drug 
treatment should be considered in patients with BPs in 
the range of 130 to 139/85 to 89 mmHg who are at high 
cardiovascular risk due to established CVD [2]. There-
fore, despite their differences in threshold for diagnosis 
of hypertension, both guidelines are in agreement that 
treatment should be considered in patients with BPs 
in the range of 130 to 139/80 to 89 mmHg if they have 
high cardiovascular risk. Here, we discuss the evidence 
for drug treatment in this subset of patients, and the 
potential benefits and harms associated with antihyper-
tensive treatment.
REDEFINING THE THRESHOLD OF 
HYPERTENSION
The differences in American and European guidelines 
regarding the BP threshold of hypertension stem from 
their differing definitions of hypertension. The Amer-
ican definition of hypertension is based on epidemio-
logic studies that convincingly show increased cardio-
vascular risk with increasing BP; compared to those 
with a BP of 115/75 mmHg, each increase in SBP/DBP of 
20/10 mmHg is associated with double the risk of death 
from stroke or coronary artery disease (CAD) [1,3]. Addi-
tionally, meta-analyses of observational studies show a 
1.5- and 2-fold higher risk of coronary heart disease and 
stroke, respectively, in subjects with BP 130 to 139/85 to 
89 mmHg compared to those with BP < 120/80 mmHg 
[1,4-6]. A recent analysis of the Korea Acute Myocardial 
Infarction Registry revealed significant elevation of the 
odds ratio (OR) for 6-month major adverse cardiovas-
cular events (MACE) in emergency department patients 
with high-normal BP and acute myocardial infarction 
(OR, 1.147; 95% confidence interval [CI], 1.011 to 1.402; p 
= 0.045) compared to patients with normal BP [7]. 
The American guideline defines hypertension as the 
BP threshold, above which the CVD risk is significantly 
increased compared to that associated with normal BP 
(130/80 mmHg) [1]. In contrast, the European guideline 
defines hypertension as the level of BP, above which 
the benefits of treatment (either with lifestyle interven-
tions or drug treatment) clearly outweigh the risks of 
treatment [2]. Irrespective of the American or European 
definitions of hypertension, due to the high prevalence 
of prehypertension in the general population, lowering 
the threshold of hypertension would result in marked 
elevation in the prevalence of hypertension and an un-
necessary increase in the risk of labeling a large portion 
of the population with a disease that they may not actu-
ally have [8,9]. 
Prior to the Systolic Blood Pressure Intervention 
Trial (SPRINT) study, no trials used the SBP inclusion 
criteria of ≥ 130 mmHg to investigate whether further 
lowering of BP would result in reduced cardiovascular 
risk [10]. However, the inclusion criteria and BP mea-
surement methods used in the SPRINT trial suggest 
that the study did not actually include treatment-naïve 
patients with SBP > 130 mmHg [10]. First, the majority 
of the patients enrolled in the SPRINT study were treat-
ed hypertensive patients, and only 2.7% of the patients 
in the intensive treatment arm and 11.3% in the stan-
dard treatment arm were considered treatment-naïve 
at randomization. As such, if these patients had been 
washed out from their medications, they would like-
ly have had BP > 140/90 mmHg. Second, the SPRINT 
study used unattended automatic office blood pressure 
(AOBP) measurement for the office BP measurement. 
As studies have shown that AOBP is 5 to 15 mmHg low-
er than manual office BP measurements, AOBP SBP of 
130 mmHg would have most likely corresponded to the 
manual office SBP of 140 mmHg, which would not dif-
fer from the previous definition of hypertension [2,11]. 
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The criteria for hypertension differ depending on 
whether the American or European guideline defini-
tion of hypertension is used. Another important and 
controversial topic is whether these subjects should be 
treated with antihypertensive medications. The lines of 
evidence that support and dispute these recommenda-
tions are presented below. 
PROS AND CONS OF MEDICAL TREATMENT 
OF SUBJECTS WITH SBP BETWEEN 130–139 
MMHG
The benefit of BP lowering treatment in patients with 
hypertension is indisputable. In a recent meta-analysis 
of 123 studies including 613,815 participants, Ettehad et 
al. [12] demonstrated that each 10 mmHg reduction in 
SBP is associated with a 20% reduction in the risk of 
major cardiovascular events, 17% reduction in the risk 
of coronary heart disease, 27% reduction in the risk 
of stroke, 28% reduction in the risk of heart failure, 
and 13% reduction in all-cause mortality. However, 
an unanswered question is whether BP lowering with 
anti-hypertensive treatment improves the outcome in 
patients with high-normal BP, defined as SBP between 
130 to 139 mmHg. The most compelling evidence re-
garding the need to treat patients with SBP above 130 
mmHg was provided by the SPRINT study, in which 
high-risk individuals with BP > 130 mmHg were ran-
domized to a target SBP of 120 or 140 mmHg [10]. The 
inclusion criteria of the SPRINT study were individuals 
> 50 years of age with at least one of the following: (1) 
history of clinical/subclinical CVD, excluding stroke; 
(2) Framingham risk score > 15; (3) aged ≥ 75 years; or (4) 
CKD with estimated glomerular filtration rate between 
20 to 60 mL/min/1.73 m2. However, as stated earlier, due 
to both the inclusion criteria and the method of office 
BP measurement, it is unclear whether the majority 
of the study population enrolled in the SPRINT study 
would have had SBP > 140 mmHg if the baseline med-
ications had been washed out and manual office BP 
measurement methods had been used for BP measure-
ments [10]. However, one finding of the SPRINT study 
was that further intensive lowering of BP in high-risk 
hypertensive patients was associated with decreased 
mortality and cardiovascular events. In addition, the 
potential benefits of intensive BP lowering in high-risk 
patients were demonstrated by Xie et al. [13], in a me-
ta-analysis of 19 clinical trials including 44,989 patients. 
In that meta-analysis, the average cardiovascular event 
rate was approximately 0.9% per year, corresponding 
to 9% to 10% per 10 years, and the average BP of the 
intensive BP lowering arm and the usual treatment 
arm was 133/76 and 140/81 mmHg, respectively [13]. The 
results showed that intensive BP lowering was asso-
ciated with a 14% reduction in cardiovascular events, 
13% reduction in myocardial infarction, 22% reduction 
in stroke, 10% reduction in albuminuria, and 19% re-
duction in retinopathy progression without significant 
reduction in heart failure, cardiovascular death, total 
mortality, or end-stage renal disease [13]. Based on this 
meta-analysis, the 2017 American guideline recom-
mends drug treatment for primary prevention in high-
risk stage 1 hypertensive patients with an arteriosclerot-
ic cardiovascular disease (ASCVD) risk score ≥ 10%, and 
in all stage 1 hypertension patients with previous CVD. 
A recent meta-analysis by Brunstrom and Carlberg [14] 
showed the association of antihypertensive treatment 
with a significant reduction in MACE, stroke, and heart 
failure in clinical trials that lowered BP in patients with 
a mean SBP of 138 mmHg and coronary heart disease. 
In addition, the aforementioned meta-analysis by Ette-
had et al. [12] revealed an association of BP lowering 
with reduced risk of major cardiovascular events, cor-
onary heart disease, stroke, heart failure, and all-cause 
mortality in subjects with baseline SBP between 130 
to 139 mmHg. In the same meta-analysis, BP lowering 
significantly reduced coronary heart disease in patients 
with baseline history of CVD whose baseline SBP was 
139 mmHg, and significantly reduced the risk of heart 
failure in patients with baseline history of CVD and 
baseline SBP of 138 mmHg [12]. Therefore, antihyper-
tensive treatment is indicated for (1) secondary preven-
tion of CVD in individuals with previous CVD, particu-
larly coronary heart disease, and SBP between 130 to 139 
mmHg; and (2) primary prevention of CVD in high-risk 
individuals with SBP between 130 to 139 mmHg. 
Several lines of evidence suggest that the above find-
ings should not be generalized to all individuals with 
SBP in the range of 130 to 139 mmHg. In the Heart 
Outcomes Prevention Evaluation 3 (HOPE-3) trial, 
12,705 subjects at intermediate cardiovascular risk were 
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randomized using a two-by-two design to receive Can-
desartan + hydrochlorothiazide, rosuvastatin or placebo 
[15]. Although antihypertensive medications failed to 
significantly reduce the primary endpoints, participants 
in the upper tertile of baseline SBP (> 143.5 mmHg) had 
significantly lower rates of first coprimary outcomes 
(defined as the composite of cardiovascular mortality, 
non-fatal myocardial infarction, and non-fatal stroke), 
and second coprimary outcomes (defined as the com-
posite of coprimary outcomes, resuscitated cardiac 
arrest, heart failure, and revascularization). However, 
antihypertensive treatment showed no benefit in sub-
jects in the middle and lower tertiles of baseline SBP 
[15]. The results from the HOPE-3 study suggest that 
BP lowering with antihypertensive treatment does not 
prevent CVD in subjects with intermediate-to-low-risk 
CVD and SBP < 140 mmHg. In a meta-analysis of BP 
treatment in individuals with high-normal and normal 
BP at baseline, subjects at high- to very-high cardio-
vascular risk derived benefit from antihypertensive 
treatment, with a 60% reduction in the risk of stroke 
(hazard ratio [HR], 0.40; 95% CI, 0.20 to 0.81). Howev-
er, subjects with low-to-moderate risk of CVD had no 
significant reduction in stroke, coronary heart disease, 
heart failure, cardiovascular death, or all-cause mortal-
ity [16]. In the aforementioned meta-analysis by Brun-
strom and Carlberg [14], 74 clinical trials including the 
data of 306,273 subjects were analyzed regarding the 
efficacy of antihypertensive treatment according to the 
baseline SBP. The results showed that antihypertensive 
treatment in patients with baseline SBP ≥ 160 mmHg 
was associated with a significant reduction in the 
risk of cardiovascular mortality, major cardiovascular 
events, coronary heart disease, stroke, and heart fail-
ure. Similarly, antihypertensive treatment in subjects 
with baseline SBP in the range of 140 to 159 mmHg was 
associated with a significant reduction in the risk of 
major cardiovascular events and coronary heart disease. 
However, antihypertensive treatment in subjects with 
baseline SBP < 140 mmHg showed no association with 
reduced risk of cardiovascular mortality, major cardio-
vascular events, coronary heart disease, or stroke [14]. 
Another important consideration in antihypertensive 
treatment is the risk of adverse events. A meta-analysis 
of 50 randomized clinical trials, which provided data 
on adverse events attributed to BP lowering treatment, 
showed that a 24% reduction in major cardiovascular 
risk factors was associated with an 89% increase in the 
risk of discontinuation, which corresponds to the pre-
vention of 33 major cardiovascular events and 84 excess 
discontinuations/1,000 patients for 5 years [17]. As such, 
the benefit of BP lowering in high-normal subjects 
should be considered with caution, and careful titration 
should be performed to minimize adverse events. In ad-
dition, excessive lowering of BP, particularly in patients 
at high risk of CAD, may increase mortality and car-
diovascular events. In a pooled analysis of the ONTAR-
GET and TRANSCEND trials, which included 30,937 
subjects at high cardiovascular risk, treating SBP < 120 
mmHg was associated with increased risk of composite 
cardiovascular outcome (HR, 1.14; 95% CI, 1.03 to 1.26), 
cardiovascular death (HR, 1.29; 95% CI, 1.12 to 1.49), and 
all-cause death (HR, 1.28; 95% CI, 1.15 to 1.42) compared 
to treated subjects with SBP between 120 to 140 mmHg 
[18]. Furthermore, a mean DBP < 70 mmHg was associ-
ated with increased risks of composite primary outcome 
(HR, 1.31; 95% CI, 1.20 to 1.42), myocardial infarction (HR, 
1.55; 95% CI, 1.33 to 1.80), hospitalization for heart failure 
(HR, 1.59; 95% CI, 1.36 to 1.86), and all-cause mortality 
(HR, 1.16; 95% CI, 1.06 to 1.28) compared to subjects with 
a mean DBP in the range of 70 to 80 mmHg [18]. Based 
on these data, the 2018 European Society of Cardiology/
European Society of Hypertension (ESC/ESH) guideline 
recommends that treated BP should not be lowered 
below 120/70 mmHg [2]. This recommendation is sup-
ported by a recent analysis of 1,234,435 participants of the 
Korean Cancer Prevention Study cohort (789,255 males, 
aged 30 to 95 years) followed up for 22.5 million per-
son-years. The study demonstrated that mortality from 
all-cause and ASCVD in those with DBP < 60 mmHg 
compared to those with DBP between 70 to 79 mmHg 
showed HRs of 1.23 (95% CI, 1.16 to 1.30) and 1.37 (95% CI, 
1.20 to 1.57), respectively [19]. 
CONCLUSIONS
The current evidence suggests that antihypertensive 
treatment may be beneficial for subjects with SBP be-
tween 130 to 139 mmHg, for primary prevention in 
those at high risk of CVD and secondary prevention for 
those with coronary heart disease. However, there is a 
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narrow therapeutic window between 120 to 130/70 to 80 
mmHg, below which there may be an increased risk of 
mortality and cardiovascular events. Therefore, careful 
titration of antihypertensive medications to lower SBP 
to 130 mmHg or below should be performed while 
ensuring that there are no adverse events. In addition, 
care should be taken to titrate the dosage to maintain 
the BP above 120/70 mmHg. No benefit of antihyper-
tensive treatment for primary prevention has been 
shown in subjects with SBP below 140 mmHg at low to 
intermediate risk of CVD.
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